Malignant mesothelioma (MM) remains a highly deadly malignancy with poor treatment option. The MM cells further promote a highly inflammatory microenvironment, which contributes to tumor initiation, development, severity and propagation. We reasoned that the anti-inflammatory actions of mesenchymal stromal cells (MSCs) and further antitumor effects of MSCs engineered to overexpress tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein (MSC-TRAIL) would effectively inhibit mesothelioma growth. Using a mouse xenograft model of intraperitoneal human mesothelioma, native mouse (mMSCs) or human (hMSC) MSCs were administered either systemically (intravenously or intraperitoneally) at various times following tumor inoculation. Both mMSCs and hMSCs localized at the sites of MM tumor growth in vivo and decreased local inflammation. Further, a trend towards decrease in tumor burden was observed. Parallel studies of in vitro exposure of nine primary human mesothelioma cell lines to mMSCs or hMSCs demonstrated reduced tumor cell migration. MSC-TRAIL exposure induced apoptosis of TRAIL-sensitive MM cells in vitro, and both mouse and human MSC-TRAIL significantly reduced the inflammatory tumor environment in vivo. Moreover, human MSC-TRAIL administration significantly reduced peritoneal tumor burden in vivo and increased tumor cell apoptosis. These proof-of-concept studies suggest that TRAIL-expressing MSCs may be useful against malignant mesothelioma.
INTRODUCTION
Malignant mesothelioma (MM) is a devastating malignancy causally associated with exposure to asbestos fibers.
1 Development of MM is associated with high levels of local pleural or peritoneal inflammation, particularly driven by the innate immune system. [2] [3] [4] The long latency of tumor development (30-40 years) and the late stage at which most patients are diagnosed contributes to the brief median survival rate (12 months). 5 The most potent currently available regimen, cisplatinum/pemetrexed, has only extended survival for an additional 6 months compared with untreated patients or 3 months compared with patients receiving cisplatinum alone. 6 Further, the regimen has significant toxicities and quality of life remains poor for most patients. A variety of other therapeutic approaches, including radiation, surgery, other drug combinations, immunotherapy and gene transfer-mediated interferon-β, have not significantly changed overall morbidity and mortality. 7 Therefore, novel therapies are desperately needed.
Mesenchymal stromal cells (MSCs) are a heterogenous population of multipotent adult cells originally isolated from the bone marrow and now found to be present in a wide range of tissues including adipose, placenta and others. 8 Current data suggest that some populations of MSCs exist as pericytes lining blood vessels where they function to modulate local inflammation. 9 Isolated MSCs have been intensely studied for use in tissue regeneration and repair, particularly in the context of potent immunomodulatory effects on the proliferation and function of a wide range of immune effector cells. [10] [11] [12] [13] [14] This occurs mostly through paracrine release of soluble mediators, but increasing evidence suggests a wider range of MSC activities involving both release of microsome particles and also direct transfer of mitochondria and other intracellular contents through cell-cell bridges. 8, 15 Further, as MSCs do not constitutively express critical cell surface antigens involved in immune recognition and rejection, non-human leukocyte antigen-matched administration of allogeneic MSCs has been increasingly investigated in a wide range of clinical immune and inflammatory disorders including graft-vs-host disease, Crohn's disease and rheumatoid arthritis. 16, 17 In parallel, a rapidly growing number of studies suggest that MSCs, either through innate anti-inflammatory actions or when engineered to express antitumor agents, can have significant effects in reducing tumor burden, metastatic disease and tumor-associated inflammatory microenvironments. [18] [19] [20] [21] [22] [23] [24] [25] However, there are only limited investigations of MSC actions in preclinical models of MM.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a naturally occurring protein, which functions to induce apoptosis by binding to the death receptor proteins expressed primarily on malignant cells. 26 MM cell lines exhibit variable levels of susceptibility to TRAIL-induced apoptosis, and recombinant TRAIL combined with chemotherapy was shown to be more effective in inhibiting tumor growth in vitro and in animal models. 27, 28 We therefore reasoned that the anti-inflammatory actions of MSCs combined with TRAIL expression might have significant effects on reducing MM tumor burden and associated inflammation. To assess this, we evaluated MSC effects on tumorigenic properties of 11 MM cell lines in vitro, and in parallel, the effects of both mouse (mMSCs) and human (hMSCs) MSCs and of MSCs engineered to overexpress TRAIL on tumor burden and inflammatory environment in a xenograft model following intraperitoneal injection of human MM cells into severe-combined immunodeficient (SCID) mice. Despite lack of adaptive immunity, these mice maintain innate inflammatory responses relevant to MM pathogenesis and are thus a good initial model for assessing MSC effects on human mesothelioma cells in vivo.
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MATERIALS AND METHODS
Cell culture mMSCs and hMSCs (bone marrow derived) were obtained from the Texas A&M Stem Cell Core facility (College Station, TX, USA). These cells have previously been extensively characterized for cell surface marker expression and differentiation capacity. 14, 29 For localization experiments, MSCs stably transduced to express cytoplasmic green fluorescent protein were used. 14, 29 For TRAIL studies, mMSCs transfected and selected for constitutive stable expression and hMSCs transduced to express doxycycline (DOX)-inducible human TRAIL protein (hMSC-FLT) were used.
14,29 All MSCs were used at passages 7-8.
The pleural MM cell lines HMESO and H2373 have been described previously.
2,30 Seven additional previously described human peritoneal MM cell lines HAY, YOU, ROB, ORT, PET, PRO and HEC 28 were generously provided by Dr Claire Verschraegen (Vermont Cancer Center, University of Vermont, Burlington, VT, USA). Human pleural MM cell lines CRL-5820 and CRL-5915 are commercially available lines from ATCC (Manassas, VA, USA). 31 In vitro analysis of tumorigenicity MSC effect on MM cell tumorigenic properties of proliferation, migration, invasion, cytokine production and anchorage-independent growth were assessed as described previously.
2 SCID mouse xenograft model of human malignant mesothelioma All animal procedures were approved by the UVM IACUC and conformed to all appropriate institutional and AAALAC standards. A previously established model of intraperitoneal inoculation of human HMESO cells into SCID mice was used. 2 In brief, HMESO cells (5 × 10 6 for localization/ tumor development experiments, 1 × 10 6 cells for MSC treatment experiments), in sterile saline, were injected intraperitoneally into male, 6-week-old Fox Chase SCID mice (Charles River Laboratories, Boston, MA, USA). 2, 32 To assess MSC localization to tumors or effect on the inflammatory microenvironment and tumor development, 1 × 10 6 MSCs or phosphatebuffered saline (control) were injected either systemically (tail vein (intravenously)) or intraperitoneally on days 27 or 7 and 14, respectively, with analysis on day 28. To assess MSC effects on peritoneal inflammation and tumor burden, tumor inoculated mice received intraperitoneal injections starting on day 21, two times a week for 3 weeks. Mice received either control injections of saline (n = 6) or 3 × 10 5 MSCs in the following groups: MSC-Alone-unmodified mMSCs or hMSCs (n = 8 each); MSCVector cells-mMSCs transfected with empty vector pCMV6-XL5 (n = 8) or hMSC-FLT cells not stimulated with DOX (n = 8); MSC-TRAIL cells-mMSC-TRAIL (clone 87) (n = 8) or hMSC-FLT cells stimulated for 72 h with DOX (n = 8). Peritoneal inflammation was assessed by measuring the total cell counts, differential cell counts, and the content of inflammatory cytokines (mouse and human) in the peritoneal lavage fluid (PLF). 2, 32 Tumor burden was assessed by collection of all tumors, including any small metastatic nodes, with detailed examination of the peritoneal and pleural cavity walls and organs. 2, 32 Tumor apoptosis was assessed by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining.
Statistical analysis
Data were evaluated by analysis of variance (ANOVA) using the Fisher's least significant difference (LSD) procedure for adjustment of multiple comparisons to the saline treatment groups and considered significant at P ⩽ 0.05. 33 P-values approaching significance noted in the figures refer to comparisons with saline controls only.
Further details on all experimental approaches are provided in the Supplementary Methods section.
RESULTS
MSCs affect migration but not proliferation, invasiveness or anchorage-independent growth of MM cell lines We initially ascertained that neither mouse nor human MSCs were induced to differentiate by MM medium components and were not killed in direct cocultures with MM cell lines (data not shown). The growth rate of the pleural MM cell lines HMESO or H2373 over 4-7 days of Transwell exposure was not significantly altered by exposure to soluble mediators from either hMSCs or mMSCs (Figure 1a) . The proliferation rate of seven additional peritoneal MM cell lines was determined and categorized as either robust, moderate or weak (Supplementary Figure 1A) . Proliferation of the robust group HAY and ORT cells was not changed during Transwell exposure to MSC-soluble mediators over days 4-7 (Supplementary Figure 1B) . Both mMSCs and hMSCs significantly inhibited the migration capacity of the four most migratory MM cell lines (HMESO, H2373, CRL-5820 and CRL-5915), following Transwell exposure for 5 days (Figure 1b) . Assessment of six other cell lines, HAY, HEC, ORT, ROB, YOU and PET, demonstrated that HAY and HEC cells were significantly inhibited only by mMSCs and hMSCs, respectively, whereas the other lines did not migrate sufficiently to determine an impact by MSCs (Supplementary Figure 1C) . All 11 cell lines exhibited only weak ability to invade across a basement membrane and no effect of exposure to either mMSCs or hMSCs by Transwell exposure was observed ( Figure 1c and Supplementary Figure 1D) . Culture of the 11 MM cell lines in anchorage-independent growth assays identified that only six of the cell lines were capable of growing colonies of significant size over 14 days (data not shown). MSCs inoculated alone into the culture system did not proliferate or form colonies and thus did not appear to contribute to the number of colonies observed (Figure 1d ). Coplating an equal number of MSCs with the HMESO cells determined that there was no change in the size or morphology of colonies formed, and the number of live cells was unaltered (Figure 1d ). These combined data indicated that exposure to MSCs does not apparently increase the tumorigenicity of MM cells. Conversely, release of the soluble cytokines TNF-α, regulated upon activation normal T-cell expressed and presumably secreted (RANTES) and interleukin-10 (IL-10) by MSCs was not affected by in vitro exposure to the 11 MM lines tested (Supplementary Figure 1E) .
MSCs home to MM tumors and alter the tumor microenvironment in SCID mice
To assess whether MSCs would localize to MM tumors in vivo, HMESO tumor-bearing SCID mice were treated (day 28) with mMSC-green fluorescent protein cells administered by either the intraperitoneal or intravenous route (Supplementary Figure 2A) . Mice were harvested 24 h later, and the tumors were qualitatively assessed for the presence of MSCs by immunofluorescent staining. Two types of intraperitoneal tumors result in this model: small free-floating spheroid tumors and tumors attached to the peritoneal mesentery.
2,32 mMSCs were found in both types of tumors, regardless of tumor size and route of administration, both at the periphery and within the tumor itself ( Figure 2 ). No mMSCs were observed within or along the periphery of the intestines or other abdominal organs (Supplementary Figures 2B and C) . There was no obvious macroscopic evidence of tumor metastasis outside the peritoneal cavity in other organs evaluated, including lung, heart and testes; therefore, we did not assess for the presence of MSCs by microscopy in other organs. Although the number of MSCs that localized to the peritoneal tumors was not quantitated, these results parallel those observed with MSC localization to tumors in a number of other models. 22 Future studies will assess quantitative MSC localization to the inoculated tumors, as we further optimize the dose and dosing regimen in this model.
The PLF was also assessed in these initial localization studies for changes in cytokines and chemokines reflecting the inflammatory microenvironment mediated by innate immune cells present in the SCID mice (Supplementary Figure 2D) . Intraperitoneal mMSC administration significantly reduced PLF levels of mouse KC, IL-12 (p70) and TNF-α, whereas only TNF-α was significantly reduced following intravenous administration. Levels of tumor origin human cytokines IL-8, VEGF (vascular endothelial growth factor) and MCAF (monocyte chemotactic and activating factor) were decreased following intraperitoneal mMSC administration; however, intravenous administration had no effect (Supplementary Figure 2D) . There was no change in total inflammatory cell numbers (macrophages, neutrophils, eosinophils) following mMSC administration, but a nonsignificant trend towards an increased percentage of neutrophils was observed in the mMSC-treated mice (Supplementary Figure 2E) .
Even in the limited immune responsiveness context of a Fox Chase SCID mouse, increased inflammation has been closely associated with MM tumor development, with the greatest peritoneal inflammation occurring on days 7 and 14 following tumor inoculation. 2, 34 To assess immunomodulatory effects and any potential effects on tumor burden if MSCs were administered during this period, tumor inoculated mice received intraperitoneal administration of mMSCs on days 7 and 14 and were subsequently assessed on day 29 ( Figure 3a) . A trend towards reduction in mesenteric but not spheroid tumor burden was observed (Figure 3b ). There was no obvious difference in the overall localization of mesenteric or spheroid tumors within the abdominal cavity. Levels of PLF mouse cytokines were not significantly changed compared with saline-treated mice, but a nonsignificant trend towards decreased levels of human MCAF and VEGF was observed (Figure 3c ). There was no significant change in total PLF cell counts, but a significant increase in the percentage of neutrophils and a decrease in the percentage of macrophages were observed, with no differences observed in the eosinophil population (Figure 3d ).
TRAIL-expressing MSCs induce MM cell apoptosis in vitro
Human TRAIL protein expression on the mouse MSC cell surface was confirmed by flow cytometry, following transfection, clonal selection and assessment of differentiation potential (data not shown). As described previously, treatment of the human MSC-FLT cells with 10 μg ml − 1 of DOX for 72 h induces TRAIL expression at the cell surface. 21 This expression once induced remains at high levels for an additional 72 h without further stimulation, before tapering off. 21 Previous microarray analysis of MM lines HMESO and H2373 identified that HMESO cells express TRAIL ligand receptors (A Shukla, unpublished data). Specifically, mRNA was present at moderate levels for both the apoptosis-inducing death receptors DR4 and DR5 and also the decoy receptor DcR2. Screening the MM cell lines following 24 h exposure to recombinant human TRAIL protein identified weakly sensitive (HMESO, H2373, HAY) and moderately sensitive (ORT, YOU) MM cells (data not shown). The effectiveness of MSC-TRAIL cells to induce apoptosis was subsequently examined on two selected MM cell lines, HMESO (weakly sensitive) and YOU (moderately sensitive). The MSCs were labeled with a cell tracker dye (CMAC (7-amino-4-chloromethylcoumarin)) for these studies and thus the MSC and MM populations were easily distinguished by flow cytometric gating. This allowed determination of the percent of early apoptotic, late apoptotic and dead MM cells following exposure to MSC-TRAIL cells (Figure 4a) . Direct coculture for 24 h with MSC-TRAIL cells (either human or mouse) increased the percentage of HMESO and YOU cells that were apoptotic (Annexin V-positive) when compared with control cell lines and positive controls (exposure to 2 μg recombinant human TRAIL). HMESO cells were more resistant to hMSC-TRAIL-induced apoptosis, just approaching significance (Figure 4b ), whereas both clones of mMSC-TRAIL cells induced significant increases in the percent of apoptotic cells (Figure 4b ). YOU cell apoptosis was significantly increased when cultured with hMSC-TRAIL cells (Figure 4c) , and also when treated with mMSC-TRAIL clone 87 (clone 49 approached significance) (Figure 4c ). MSC-Vector cells also increased the apoptotic cell number, although not at the significant levels observed in the TRAIL-expressing cells, but greater than that in control exposures using recombinant human TRAIL protein itself (Figures 4b and c) . These data indicate that MSCs alone elicit a modest proapoptotic effect, through as yet unclear mechanisms. However, expression of TRAIL further increases apoptosis of the tumor cells. Figure 3A) . mMSC-TRAIL administration (clone 87) had no significant effect on tumor burden (Supplementary Figure 3B) . There was no change in the percent of different inflammatory cell components within the PLF; however, a significant reduction in the PLF total neutrophil count was observed in mMSC-Vector-and mMSC-TRAIL-treated mice (Supplementary Figure 3C) . Administration of mMSC-Alone significantly reduced PLF levels of mouse interferon-γ and approached significance in MIP-1α, whereas mMSC-Vector and mMSC-TRAIL administration significantly reduced MIP-1α but only approached significance in interferon-γ (Supplementary Figure  3D) . A nonsignificant overall trend toward reduced levels of mouse IL-1rα, IL-2, Eotaxin, KC, MCP-1 (MCAF) and TNF-α was observed following administration of mMSC-Alone, mMSC-TRAIL or mMSC-Vector cells. Significant reductions, compared with saline control, were found in PLF levels of human IL-1rα, IL-1β, IL-15, basic FGF, GM-CSF, MIP-1α and RANTES following administration of mMSC-Alone or mMSC-TRAIL (Supplementary Figure 3E) . Levels of human IL-10 and VEGF exhibited a nonsignificant trend towards decrease. Administration of mMSC-Vector cells produced similar but nonsignificant trends towards decrease in levels of these cytokines. No significant changes occurred in human TNF-α for any treatment group. Comparison of mMSC-TRAIL administration to control cell lines mMSC-Alone or mMSC-Vector showed a synergistic effect of the combinatorial MSC+TRAIL administration only in reducing levels of IL-1rα when compared with MSC-Vector (Supplementary Figure 3E) . Sections of tumor were analyzed for levels of apoptosis by staining for TUNEL. Compared with saline controls in which minimal TUNEL staining was observed, tumors from mice treated with either mMSC-Alone or mMSC-TRAIL cells exhibited increased levels of TUNEL-positive cells (Supplementary Figure 3F) .
In contrast to mMSC-TRAIL, TRAIL-expressing hMSCs significantly reduced tumor burden compared with saline controls (Figure 5b) . Administration of hMSC-Alone or hMSC-Vector cells also produced a trend towards reduced tumor burden, but this was not significant compared with saline controls. However, the hMSC effect on tumor burden (either Alone or Vector control) was such that the comparison of MSC-TRAIL with either control group was not additionally significant. hMSC administration (Alone, Vector and TRAIL) significantly increased the percentage of neutrophils within the PLF cell population (Figure 5c ), but had no significant effect on the number of total inflammatory cells. Levels of murine CD45 mRNA expression, an index of infiltrating inflammatory cells in the tumors, was not altered in any group examined compared with saline controls (data not shown). Minimal TUNEL staining was observed in saline controls, whereas in comparison, tumors from mice treated with either hMSC-Alone or hMSC-TRAIL cells exhibited increased levels of TUNEL-positive cells (Figure 5d) , with the greatest levels observed in hMSC-TRAILtreated tumors, indicating that the reduction in tumor burden was correlated with an increase in apoptosis within the tumors.
hMSC administration further significantly decreased the levels of multiple PLF cytokines and chemokines (both mouse and human) in this model. Administration of hMSCs (all groups) significantly reduced the levels of mouse IL-2, IL-3, IL-10, IL-12 (p70) (excluding hMSC-Vector), GM-CSF, MIP-1β and TNF-α (Figure 6a ). hMSC-TRAIL treatment also significantly reduced mouse IL-1β and IL-13, whereas hMSC-Alone treatment significantly reduced mouse IL-4 and IL-17. Levels of interferon-γ were reduced in every category (hMSC-Alone was not analyzed as only a single data point was above the level of detection) (Figure 6a) . Comparison of hMSC-TRAIL administration with hMSC-Alone or hMSC-Vector showed a synergistic effect of the combinatorial MSC +TRAIL in reducing levels of mouse GM-CSF and TNF-α when compared with MSC-Vector, and in TNF-α when compared with MSC-Alone (Figure 6a ).
Significant reductions were observed in PLF levels of human IL-1β, IL-10, IL-12(p70), MCP-1(MCAF), RANTES, TNF-α and VEGF following hMSC-TRAIL administration, whereas hMSC-Alone and hMSC-Vector had a minimal impact (Figure 6b) . Comparison of hMSC-TRAIL with controls showed that the combinatorial MSC+TRAIL administration was significant in reducing levels of IL-1β, IL-10, RANTES and TNF-α when compared with hMSC-Alone. However, the trend towards reduction in hMSC-Vector resulted in no significant differences when compared with hMSC-TRAIL (Figure 6b ).
In parallel with the earlier studies, hMSC administration resulted in a significant reduction in the PLF mouse and human TNF-α (Figure 6a and b) , whereas mMSC administration significantly reduced mouse, but not human, TNF-α in the 24 h colocalization study (Supplementary Figure 2D) . The same trend was observed in mouse, but not in human, TNF-α following mMSC administration ( Supplementary Figure 3d and e) .
DISCUSSION
Following systemic or intraperitoneal administration, otherwise unmodified mMSCs or hMSCs could be located in tumors and decreased peritoneal inflammation in an in vivo mouse xenograft A rapidly growing literature demonstrates the effectiveness of MSC-based therapy approaches in a variety of preclinical inflammatory disease models. 35 There are a growing number of clinical trials of MSC therapy in inflammatory and immune-based diseases, including recent approval for MSC use in severe refractory pediatric graft-vs-host disease in Canada. 36 Importantly, there have been no significant safety concerns or adverse events on follow-up in these inflammation-focused trials. 37, 38 These findings suggest that MSC-based cell therapy approaches may be particularly appealing for some cancer therapies, although the impact of immunosuppression in cancer and the possible contribution of MSCs to surrounding stroma in some types of cancers 35 will require continued study. Notably, MSCs home to areas of both primary and metastatic tumors, through chemotactic . Significance compared with saline control is indicated as *P ⩽ 0.05, **P ⩽ 0.01 and ***P ⩽ 0.001. pathways, are still being elucidated. 11 MSCs can also alter the tumor microenvironment and decrease inflammation, an important potential therapeutic effect for inflammatory tumors such as MM. [39] [40] [41] Other studies have described this innate MSC antitumorigenic effect in a number of cancer models, 35 thus establishing a potential role for MSCs as non-immunogenic cellbased cancer therapy. Further, a growing literature suggests that engineered MSCs may be even more potent antitumor agents. MSCs have been transfected or transduced with recombinant viral vectors to express antitumor compounds including Bcl-2 and TRAIL. [18] [19] [20] [22] [23] [24] [25] In particular, recombinant viral transduction of MSCs with human TRAIL has been shown to inhibit effectively in vivo progression of lung cancer, 22 as well as a variety of primary and metastatic tumors including glioma and breast carcinoma. 19, 21, 25 MSC-TRAIL also suppressed proliferation of pancreatic cancer lines in vitro 23 and overcame TRAIL resistance in in vivo colorectal cancer models. 24 Combination of a dodecameric TRAIL vector combined with MSCs engineered to overexpress HSV-TK protein was able to inhibit completely metastatic renal cell carcinoma in a preclinical model. 20 With respect to MM, recombinant TRAIL peptides have been demonstrated to induce apoptosis in several MM cell lines. 27 A recent study demonstrates that the same TRAIL-expressing hMSCs used in this study were able to reduce tumor burden in a xenograft model of human mesothelioma cells inoculated into the pleural cavity. 42 This study further extends and corroborates those initial findings in a peritoneal model. The current study also includes detailed assessments of MSC effects on the proinflammatory peritoneal environment produced in the xenograft model. Our data confirm the induction of MM cell apoptosis observed in vitro when treated with MSCs alone or expressing TRAIL, 42 and further determines the effects of MSCs alone on MM tumorigenesis using standard in vitro assays, aspects that had not previously been assessed in the pleural study.
Acknowledging the limitations of assessing inflammatory pathways in immunocompromised SCID mice, innate immune responses are maintained and there were a number of intriguing findings. Both unmodified and modified MSCs altered the tumor Figure 6 . Human mesenchymal stromal cell-tumor necrosis factor-related apoptosis-inducing ligand (hMSC-TRAIL) cell therapy alters soluble cytokines of the tumor microenvironment. Bioplex analysis of soluble inflammatory cytokines within peritoneal lavage fluid (PLF) of mice therapeutically treated with hMSCs identified significant reductions in (a) mouse and (b) human soluble cytokines. All units are represented as pg ml − 1 (mean ± s.e.m.); histogram colors-saline control, white; hMSC-Alone, light gray; hMSC-Vector, dark gray; hMSC-TRAIL, black (n = 5, saline control; n = 8, hMSC-Alone; n = 7, hMSC-Vector; and n = 8, hMSC-TRAIL). Significance as determined by analysis of variance (ANOVA) with a Fisher's least significant difference (LSD) posttest is indicated as *P ⩽ 0.05, **P ⩽ 0.01 and ***P ⩽ 0.001 with respect to saline levels. Significant changes between hMSC-TRAIL treatment and hMSC-Alone or hMSC-Vector are indicated by the symbols # and @, respectively, and significance is indicated as P ⩽ 0.05 level only. The addition of P-values approaching significance in the figure represent comparison with saline controls only. microenvironment through both the reduction in soluble inflammatory mediators, and inducing a shift in the peritoneal inflammatory cell profile. Both of these actions may affect proand antitumorigenic pathways. 43, 44 As MM is a highly inflammatory tumor, and local inflammation is postulated to contribute to both MM survival and proliferation, 39, 45 this may be a significant mechanism by which MSC-based therapy could impact clinical MM. As such, these hypothesis-generating observations will be further explored in syngenic-immunocompetent allograft models of mouse MM. 46 Nonetheless, our findings are in keeping with many observations demonstrating the ability of MSCs to decrease inflammatory tumorigenic environments. 11, 13 We also found that membrane-bound human TRAIL expression on either human or mouse MSCs induced apoptosis in multiple human MM cell lines in vitro. Notably, there can be differences in actions of MSCs obtained from mice vs human and soluble antiinflammatory cytokines released by human MSCs may not be appropriately recognized by murine inflammatory, immune and other relevant effector cells. Thus, as the overall goal is to develop a strategy for use of human MSCs in mesothelioma, it was important to include both in these initial studies. Importantly, use of human TRAIL-expressing hMSCs in the in vivo model resulted in a significant decrease in tumor burden as well as in inflammation. Although hMSCs alone or hMSCs transduced with an empty vector produced trends towards decreased tumor burden, only the TRAIL-expressing hMSCs produced significant decreases compared with saline controls. As treatment with recombinant TRAIL (which has a limited half-life around 30 min 42 ) did not significantly increase apoptosis in vitro (Figure 4 ), we did not include an arm in which recombinant TRAIL peptide alone was administered, but this will be included in future larger-scale studies. In some cases, synergistic decrease in inflammatory cytokines were observed compared with the administration of non-TRAIL-expressing MSC controls. In contrast, TRAIL-expressing mouse MSCs decreased inflammation but had no significant effect on tumor burden. The transfected mouse MSCs constitutively express human TRAIL, whereas the transduced human MSCs are induced with DOX, and this induction results in very high expression for 3-4 days, before tapering off. Therefore, two doses a week were given to achieve and maintain consistent expression. Identifying whether the potential difference in MSC dose, quantitation of MSC localization to tumor or species difference of the MSCs is the key factor in the different results observed will need to be examined in future larger-scale studies. Notably, both mouse and human MSCs, regardless of TRAIL expression, stimulated tumor apoptosis but had no significant effects on the number of infiltrating leukocytes. These initial findings will be more extensively explored in future studies, including those in immunocompetent mouse allograft MM models. As these results parallel a number of similar results following administration of MSCs in other cancer models, we did not include an arm with a control (non-MSC) cell line in these initial studies but will do so in future investigations.
Recent data suggest that one potential antitumor action of MSCs is through TNF-α signaling. In the context of high levels of nuclear factor-κB, TNF-α functions as a prosurvival signal, 47 a trait observed in many MM tumor lines. 1, 5, 39 Notably, MSC secretion of TSG-6 can inhibit nuclear factor-κB signaling, 48 whereas macrophages cocultured with MSCs exhibited lower TNF-α, 49 and TNF-α stimulation of MSCs activated innate TRAIL levels. 50 In the current studies, depending on the model used, both mMSCs and hMSCs suppressed TNF-α levels, MSC-TRAIL treatment synergistically reduced these levels and the consistent reduction of both mouse and human TNF-α correlated with the reduction in tumor size observed in hMSC-TRAIL therapy. This suggests that inhibition of TNF-α may be a means of breaking the prosurvival signal to allow apoptosis to occur, as seen in the TUNEL staining, and the addition of TRAIL at high levels induces further apoptosis, sufficient to inhibit tumor development. Investigation of TNF-α knockdown in combination with MSC therapy will be a key element of future studies analyzing the mechanism of MSC function.
The 25% reduction in tumor burden observed in the HMESO xenograft MM model, with its high inflammation and only poormoderate TRAIL-sensitive status, suggests a significant and potentially clinically relevant MSC impact within the constraints of this model. In addition, as inflammation is critical to the pathogenesis, evolution and maintenance of MM tumors, decrease in inflammatory parameters, even within the constraints of the SCID model used, suggest further potential clinical utility of MSC administration in MM. 46, 51 Therefore, these proof-of-concept studies set the groundwork for more extensive future investigations, while highlighting the potential of MSCs as a potential cotherapy for MM.
